BETA

12 Amendments of Zofija MAZEJ KUKOVIČ related to 2011/0402(CNS)

Amendment 86 #
Proposal for a decision
Annex 1 – point 4 – paragraph 7
Further public-public partnerships and public-private partnerships may be launched under Horizon 2020 where they meet the defined criteria. This may include partnerships on Iinformation and Ccommunication Ttechnologies in the areas of Pphotonics and Rrobotics, on sustainable process industries, on bio-based industries, on telemedicine and home treatment appliances, and on security technologies for maritime border surveillance.
2012/06/20
Committee: ENVI
Amendment 119 #
Proposal for a decision
Annex 1 – part III – point 1 – paragraph 2 a (new)
Research gaps in the area of infectious, poverty-related, and neglected diseases must be addressed through research and innovation activities driven by patients’ needs. By supporting innovative global partnerships to develop prevention, diagnostic, treatment, and telemedicine tools, excellent science can be accelerated, and the Union can respect its global commitments.
2012/06/20
Committee: ENVI
Amendment 121 #
Proposal for a decision
Annex 1 – part III – point 1 – paragraph 3
An increasing disease and disability burden in the context of an ageing population places further demands on health and care sectors. If effective health and care is to be maintained for all ages, efforts are required to improvespeed up decision -making inand awareness-raising in disease prevention and treatment provision, to identify and support the dissemination of best practice in the healthcare sector, and to support integrated care and the uptake of technological, organisational and social innovations empowering older persons in particular to remain active and independent. Doing so will contribute to increasing, and lengthening the duration of, their physical, social, and mental well- being.
2012/06/20
Committee: ENVI
Amendment 134 #
Proposal for a decision
Annex 1 – part III – point 1 – point 1.4 – paragraph 1
There is a need for an improved understanding of health and disease, in people of all ages, so that new and better prevention measures, diagnosis and treatments can be developed. Interdisciplinary, translational research on the patho-physiology of disease is essential to improve the understanding of all aspects of disease processes, including a re- classification of normal variation and disease based on molecular data, and to validate and use research results in clinical applications. Translational research projects aimed at applying laboratory findings more quickly and efficiently into medical practice should be particularly supported, especially in those areas of high unmet need, such as haematology/oncology, rare diseases and antimicrobial resistance.
2012/06/26
Committee: ENVI
Amendment 138 #
Proposal for a decision
Annex 1 – part III – point 1 – point 1.5 – paragraph 1
There is a need forto support the development of more effective preventive vaccines (or alternative preventive interventions) and evidence- based vaccination schemes fand evidence-based vaccination schemes for an expanded range of diseases, including poverty-related diseases such as HIV/AIDS, tuberculosis, malaria and neglected diseases. Similarly, knowledge about the main risk factors of disease, as well as behavioural science, can be used to devise effective prevention strategies addressing these risk factors an expanded rd aiming at promoting healthy lifestyles and the importangce of diseases. Thishealthy food. This has a tremendous potential to reduce the burden of chronic diseases, but relies on a better understanding of disease and disease processes and their consequent epidemics, and thaton clinical trials and associated studies arebeing undertaken.
2012/06/26
Committee: ENVI
Amendment 145 #
Proposal for a decision
Annex 1 – part III – point 1 – point 1.11 – paragraph 1
There is a need to support the development of scientific tools, methods and statistics for rapid, accurate and predictive assessment of the safety, efficacy and quality of health technologies including new drugs, biologics, advanced therapies and medical devices. This is particularly relevant for new developments in domains including those concerning vaccines, cell/tissue and gene therapies, organs and transplantation, specialist manufacturing, bio banks, new medical devices, diagnostic/treatment procedures, genetic testing, interoperability, telemedicine and e-health, including privacy aspects. Similarly, support for improved risk assessment methodologies, testing approaches and strategies relating to environment and health are required. There is also a need to support the development of relevant methods for assisting the assessment of ethical aspects of the above domains.
2012/06/26
Committee: ENVI
Amendment 154 #
Proposal for a decision
Annex 1 – part III – point 2 – title
2. Food safety, healthy food and food security, sustainable agriculture, marine and maritimeountain research and the bio- economy
2012/06/26
Committee: ENVI
Amendment 168 #
Proposal for a decision
Recital 8
(8) In order to maintain and increase the Union's industrial leadership there is an urgent need to stimulate private sector research and development and innovation investment, promote research and innovation with a business driven agenda and accelerate the development of new technologies which will underpin future businesses and economic growth. Part II "Industrial leadership" should support investments in excellent research and innovation in key enabling technologies and other industrial technologies, facilitate access to risk finance for innovative companies and projects, and provide Union wide support for innovation in small and medium-sized enterprises, primarily by lowering the entry threshold for small and medium-sized enterprises.
2012/07/03
Committee: ITRE
Amendment 374 #
Proposal for a decision
Annex 1 – point 4 – paragraph 7
Further public-public partnerships and public-private partnerships may be launched under Horizon 2020 where they meet the defined criteria. This may include partnerships on Information and Communication Technologies in the areas of Photonics and Robotics, on sustainable process industries, on bio-based industries and, on telemedicine and home treatment appliances, on security technologies for maritime border surveillance.
2012/07/03
Committee: ITRE
Amendment 597 #
Proposal for a decision
Annex 1 – section 3 – point 1 – paragraph 4
All of these activities will be undertaken in such a way as to provide support throughout the research and innovation cycle, strengthening the competitiveness of the European based industries and SMEs and development of new market opportunities.
2012/07/05
Committee: ITRE
Amendment 642 #
Proposal for a decision
Annex 1 – section 3 – point 1 – point 1.11 – paragraph 1
There is a need to support the development of scientific tools, methods and statistics for rapid, accurate and predictive assessment of the safety, efficacy and quality of health technologies including new drugs, biologics, advanced therapies and medical devices. This is particularly relevant for new developments in domains including those concerning vaccines, cell/tissue and gene therapies, organs and transplantation, specialist manufacturing, bio banks, new medical devices, diagnostic/treatment procedures, genetic testing, interoperability, telemedicine and e-health, including privacy aspects. Similarly, support for improved risk assessment methodologies, testing approaches and strategies relating to environment and health are required. There is also a need to support the development of relevant methods for assisting the assessment of ethical aspects of the above domains.
2012/07/05
Committee: ITRE
Amendment 664 #
Proposal for a decision
Annex 1 – section 3 – point 2 – introductory part
2. Food safety, healthy food and food security, sustainable agriculture, marine and maritimeountain research and the bio- economy
2012/07/05
Committee: ITRE